Literature DB >> 17914604

Hepatitis C virus entry into host cells.

F Helle1, J Dubuisson.   

Abstract

The recent development of functional models to analyze the early steps of the hepatitis C virus (HCV) life cycle has highlighted that HCV entry is a slow and complex multistep process involving the presence of several entry factors. Initial host cell attachment may involve glycosaminoglycans and the low-density lipoprotein receptor, after which the particle appears to interact sequentially with three entry factors: the scavenger receptor class B type I, the tetraspanin CD81 and the tight-junction protein claudin-1. Several serum components may also modulate HCV entry, while the recently discovered CD81 partner EWI-2wint can block the interaction of the viral particle with CD81, potentially preventing infection in the cell types in which it is expressed. After binding to the host cell, the HCV particle is internalized by clathrin-mediated endocytosis, with fusion likely occurring in early endosomes. This review summarizes our current knowledge on HCV entry.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17914604     DOI: 10.1007/s00018-007-7291-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  56 in total

1.  Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.

Authors:  Huahao Fan; Luhua Qiao; Kyung-Don Kang; Junfen Fan; Wensheng Wei; Guangxiang Luo
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

3.  The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection.

Authors:  Jian Tao; Kyung-Don Kang; Stacy D Hall; Audra H Laube; Jia Liu; Matthew B Renfrow; Jan Novak; Guangxiang Luo
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

4.  Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain.

Authors:  Gopal Sapparapu; Stephanie A Planque; Yasuhiro Nishiyama; Steven K Foung; Sudhir Paul
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

5.  Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.

Authors:  Nishi R Sharma; Guaniri Mateu; Marlene Dreux; Arash Grakoui; François-Loïc Cosset; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

6.  Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

Review 7.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

8.  Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain.

Authors:  Jillian Whidby; Guaniri Mateu; Hannah Scarborough; Borries Demeler; Arash Grakoui; Joseph Marcotrigiano
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

9.  The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Authors:  Eve-Isabelle Pécheur; Viktoriya Borisevich; Peter Halfmann; John D Morrey; Donald F Smee; Mark Prichard; Chad E Mire; Yoshihiro Kawaoka; Thomas W Geisbert; Stephen J Polyak
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

10.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.

Authors:  Jeroen Witteveldt; Matthew J Evans; Julia Bitzegeio; George Koutsoudakis; Ania M Owsianka; Allan G N Angus; Zhen-Yong Keck; Steven K H Foung; Thomas Pietschmann; Charles M Rice; Arvind H Patel
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.